Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATATE in Rare Metastatic Endocrine Carcinomas
NCT04106843Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2019
- Primary completion
- Sep 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in medullary thyroid carcinoma (MTC), parathyroid carcinoma, Pituitary carcinoma (PC) and 2 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 52 weeks. Planned start Jun 2019; status: withdrawn.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
medullary thyroid carcinoma (MTC)parathyroid carcinomaPituitary carcinoma (PC)pheochromocytomamalignant paraganglioma
Beyond the preview
Go deeper on NCT04106843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04106843.